focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
There are 251m Avacta shares giving Avacta a Market Cap at ÂŁ 131m, (previously > ÂŁ 700m)
On an average day, 2.2m Avacta shares are traded.
One day last week, 6m shares were traded. yesterday, 5.2m shares were traded.
The share price is currently dropping on a daily basis.
Time to Batten Down the Hatches and ride out the storm!
Summary:
Avacta has cash in the Bank.
Avacta has global partnerships that bring in revenue.
Avacta will have new global partnerships that will bring in additional revenue.
Avacta has innovative and life saving science.
Avacta has game changing Precision products in clinical trials.
The clinical trials are going well.
When the clinical trials succeed, Avacta will soar.
Something here is not right and we private investors cannot influence the market. If you believe in Avacta, and the multiple PHD Scientists working there, you need to be brave and ride out this storm.
I have dug in, set funds aside and am willing to wait for the BIG OUTCOME, …..
As ever, GLA and DYOR.
@Pharma3 and other LTI's
When you walk through a storm
Hold your head up high
And don't be afraid of the dark
At the end of a storm
There's a golden sky
And the sweet silver song of a lark
Walk on through the wind
Walk on through the rain
Though your dreams be tossed and blown
Walk on, walk on
With hope in your heart
And you'll NEVER WALK ALONE
There are 251m Avacta shares giving Avacta a Market Cap at ÂŁ 131m, (previously > ÂŁ 700m)
On an average day, 2.2m Avacta shares are traded.
One day last week, 6m shares were traded. today, 5.2m shares were traded.
The share price is currently dropping on a daily basis.
Time to Batten Down the Hatches and ride out the storm!
Summary:
Avacta has cash in the Bank.
Avacta has global partnerships that bring in revenue.
Avacta will have new global partnerships that will bring in additional revenue.
Avacta has innovative and life saving science.
Avacta has game changing Precision products in clinical trials.
The clinical trials are going well.
When the clinical trials succeed, Avacta will soar.
Something here is not right and we private investors cannot influence the market. If you believe in Avacta, and the multiple PHD Scientists working there, you need to be brave and ride out this storm.
I have dug in, set funds aside and am willing to wait for the BIG OUTCOME, …..
As ever, GLA and DYOR.
50% of the UK population will be diagnosed with some form of cancer during their lifetime.
Approximately 375,000 people are diagnosed with Cancer in the UK each year.
Sadly, 166,000 (44%) of these people will not survive.
https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk
The number diagnosed in the USA is 1,600,000 and, once again, the terminal numbers are bleak at around 600,000 (38%).
Long term investors are familiar with Avacta’s Therapeutics division and the opportunities to offer life saving treatments with the pre|CISIONTM products, (AVA6000, AVA3996, etc).
The latest AVA6000 news is positive and is expected the get better as the dosing increases.
“Pre|CISIONTM can open up an extensive and proprietary pipeline for Avacta of next-generation pre|CISIONTM pro-drug chemotherapies with significant clinical and commercial advantages in a chemotherapy market that is expected to exceed $74 billion by 2027.”
https://avacta.com/avacta-announces-first-patient-dosed-in-ava6000-pro-doxorubicin-phase-1-clinical-trial/
If Precison allows more aggressive treatment of cancers and can reduce fatalities by 25%, that’s 190,000 lives saved every year in the UK and USA alone. The survival rates can be much higher.
I would value that at more than ÂŁ 0.60 per share!
@EnergyShares, also, ....
Covid: Self-isolation law could be scrapped in England this month
https://www.bbc.co.uk/news/uk-60319947
Current HM Government approved LFT list expires end of this month.
Coincidence?
The general consensus is to stick with Avacta.
09:00 UK time, 450K traded and the share price appears to have settled.
WE just need the Institutional Investors to come in with confidence and make some VERY BIG BUYS.
There were 6.1m Avacta shares traded yesterday which is x3 the daily average (2m).
Some financial institutions have taken up short positions with Avacta and are taking the LFT news as an opportunity to make money. There is a need for LFT’s but not sure when Avacta and Medusa19 will bring MeduFlow to market? Avacta also have plans for other non-Covid diagnostic products.
The positive news is that AVA6000 trials are progressing well and this is BIG news for the cancer market. Avacta Precision offers many lifesaving opportunities.
Hargreaves Lansdown (HL) is one of the largest investors in Avacta and this implies many private investors who will now be sitting on paper losses. It is painful but only a loss when you actually sell.
We will have to wait for more news and I would not expect any ground breaking RNS statements in the short term.
Read the content on the Avacta website more than some of the comments written here. There are some who prefer to be negative so you have the option to read and worry of use the filter option.
AS has previously commented that Avacta can become another Roche (ÂŁ 46bn turnover) and the science is progressing.
Personally, I am staying with Avacta for the science and the opportunity.
As ever, DYOR and GLA
@Templar
You last post highlights the opportunity.
Based on the current share price, Avacta market cap is currently $ 230m.
An offer for Avacta at $ 1bn would put us back at ÂŁ 3 per share, (nice at the moment).
Agree that the science and the opportunity are immense.
Just need to hold our nerves.
Rather than remove AS, perhaps a big pharma (with a proven CEO, Sales & Marketing Department, Manufacturing Capacity, etc.) needs to acquire Avacta’s innovative IP and bring it to market in volume.
AS can stay in situ’ with the current team and continue to develop the science. The bigger operation with the required infrastructure will bring products to market for the benefit of all mankind.
What’s this unique IP worth?
More than ÂŁ 190m?
Do not panic.
The price was manipulated at close on Friday and this drop was expected.
Sit tight and wait for action and updates over the coming days and weeks.
RE: S/P04 Feb 2022 17:18
@Toatie
Share price being manipulated.
Last minute trades push the price up to ÂŁ 0.95 but it will open at ÂŁ0.84 on Monday.
08:01 Monday, look like the share price is down ÂŁ 0.11 (12%) and people panic.
How this manipulation can be legal in the UK, I do not know.
Stick with it. The science will prevail in the end!
GLA
Avacta held 3 days of presentations with institutional investors (II’s) last week. These II’s would have been told about Precision (AVA6000), LFT’s and other exciting products in the Avacta pipe-line.
AVA6000 trials are progressing well and this science will be of great interest to the big pharma’s. There are opportunities for multiple licensing deals or perhaps the acquisition of Avacta. The science is life saving.
There is a perception that the worst of Covid may be over and this is not the case. The overseas holidays that we all took for granted now require travellers to be fully vaccinated, a PCR test 3 days prior and an LFT 24 hours before going to the airport. Subject to the holiday destination, other testing (LFT’s) may be required.
The market for LFT’s remains and, with the Medusa 19 partnership, there is a short term opportunity for Avacta to benefit from LFT income. Waiting LFT update.
The Avacta share price has taken a hammering recently. Most believe the share price is being manipulated and that the current levels do not represent the true value of Avacta.
Avacta has cash in the bank. There are opportunities for income from stage payments, licencing and LFT sales. The science is progressing and the Avacta story continues to progress.
In closing, still have faith in the company and the science. Currently sitting on a paper loss but will continue to sit and follow Avacta’s development and growth.
Hopefully private investors will be updated next week and perhaps we may get an LFT RNS?
As ever, DYOR and GLA
@Toatie
Share price being manipulated.
Last minute trades push the price up to ÂŁ 0.95 but it will open at ÂŁ0.84 on Monday.
08:01 Monday, look like the share price is down ÂŁ 0.11 (12%) and people panic.
How this manipulation can be legal in the UK, I do not know.
Stick with it. The science will prevail in the end!
GLA
Avacta will be presenting to institutional investors this week. Among the investors will be Hargreaves Lansdown (HL) which is also a vehicle for private investors.
According to Market Screener, Hargreaves Lansdown (HL) currently holds 22% of Avacta’s stock. The bulk of this stock will be held by private investors. (https://www.marketscreener.com/quote/stock/AVACTA-GROUP-PLC-4004322/company/)
My Avacta investment is with HL and is sitting in SIPP’s and ISA’s. I am not an institutional investor but have a significant investment. I, like many, (MM) would expect visibility of the presentations over the next 3 days. If not, is it insider trading by the II's?
Question: Has anyone read anything relating to private investor information share?
Here’s to positive news, Avacta success, institutional investment and a rising share price.
(GLA).
There is a great deal to tell over 3 days. The status November 2021 was, ...
Investment Opportunity
Avacta’s proprietary Affimer® and pre|CISION™ (targeted chemotherapy) platforms are delivering a robust portfolio of differentiated therapeutic and diagnostic products that address multiple multi-billion dollar markets. The market oportunity exceeds $ 100bn.
Avacta’s Affimer-based rapid Covid-19 antigen test due for commercial roll-out by end Q1.
With its strong balance sheet, the Group expects to deliver major value inflection points from its well-funded therapeutic programmes over the next 12 months.
Current significant shareholders are as follows:
Premier Miton Group – 4.66%
Baillie Gifford & Co Limited – 4.63%
Conifer Management, LLC – 2.99%
As at 3rd November 2021 the company has 253,712,353 ordinary shares of 10p each in issue.
Avacta Group has not applied or agreed to have any of its securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms. Avacta Group plc is subject to the UK City Code on Takeovers and Mergers.
Advisors
Broker and Nomad – Stifel, 150 Cheapside, London, EC2V 6ET
Auditor – BDO LLP, Newton House, Cambridge Business Park, Cambridge, CB4 0WZ
Solicitor – Walker Morris, 33 Wellington Street, Leeds, LS1 4DL
Registrar – Link Group, 10th floor, Central Square, 29 Wellington Street, Leeds, LS1 4DL.
Above available at https://avacta.com/investors/key-information/
GLA
Those who bought at the start of the week have experienced a 30% increase in the share price. Some will be happy to take the profit from short term trading. With big news imminent, not sure that I would want to be out of Avacta over the next few weeks.
Big AVA6000 and LFT news is coming, …
@54retiresoon
There will be Investment Companies who are unfamiliar with the full Avacta offering or who see Avacta as a Covid LFT company. Correcting this misconception can create share demand and an increase in share value.
Large Avacta investors (share quantity) at the moment include:
(https://www.marketscreener.com/quote/stock/AVACTA-GROUP-PLC-4004322/company/)
- Hargreaves Lansdown Stockbrokers Ltd. (43,330,000) 17.1%
- Jarvis Investment Management Ltd. (21,397,000) 8.43%
- Hargreaves Lansdown Asset Management Ltd. (15,252,000) 6.01%
- Premier Fund Managers Ltd. (11,609,794) 4.57%
- Baillie Gifford & Co. (11,515,758) 4.53%
- Lombard Odier Asset Management (Europe) Ltd. (9,979,863) 3.93%
- J.O. Hambro Capital Management Ltd. (8,625,000) 3.40%
- Carlton International Holdings Ltd. (8,400,000) 3.31%
- Conifer Management LLC (7,575,786) 2.98%
- Unicorn Asset Management Ltd. (6,000,000) 2.36%
There are also private investors holding significant holdings in Avacta, (Myles M).
Avacta have previously used Investor Meet the Company. For those who have not registered, suggest that you register and demand (request) a DDM (Demand Driven Meeting). If there is a high level of demand from PI’s, it should flag with Avacta and generate a meeting/update.
https://www.investormeetcompany.com/investor/companies